250 filings
Page 7 of 13
8-K
ygr88
12 Jan 18
Other Events
12:00am
8-K
w5kl dccrsm1devq
5 Jan 18
Other Events
12:00am
8-K
m6zdsl
19 Dec 17
Other Events
12:00am
8-K
ekrh69i0i6l8vghkye
30 Nov 17
Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
12:00am
8-K
svth4gy
2 Nov 17
Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results
12:00am
8-K
afjcmdfsea012ip 7qv
31 Oct 17
Other Events
12:00am
8-K
o06308ewk3q
30 Oct 17
Entry into a Material Definitive Agreement
12:00am
8-K
7pj76s
27 Sep 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
dh28ob
20 Sep 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
5lfz3yr2
5 Sep 17
Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
12:00am
8-K
goh2lio
4 May 17
Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results
12:00am
8-K
cpq2mwssfljhfg
4 Apr 17
Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
12:00am
8-K
jod7v4b7
3 Apr 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
7vytq 3n8d87gwu
13 Feb 17
Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
12:00am
8-K
ws9etnbskzh6rjee
3 Feb 17
Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
12:00am
8-K
awdrc5oxhov14uif
2 Feb 17
Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
12:00am
8-K
r56sly
9 Jan 17
Regulation FD Disclosure
12:00am
8-K
j0o67gez uyxd1kzs
10 Nov 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
6aqskfpoymeus
3 Nov 16
Aviragen Therapeutics Reportsfirst Quarter Fiscal Year 2017FINANCIAL Results
12:00am
8-K
i085pxm33mhs2wm
11 Oct 16
Other Events
12:00am